CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 44 enrolled
Drug / intervention
Propranolol +1 moredrug
Likely dose
Propranolol 40mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03309943
NCT03309943Phase 4Completed

Neurobehavioral Substrates of Propranolol's Effects on Drug Cue Reactivity

Duke University·interventional·Posted Oct 16, 2017·Updated Aug 13, 2020

In Brief

A Phase 4 clinical trial evaluating Propranolol and Placebo for Cigarette Smoking. Completed, enrolled 44 participants across 1 site.

Detailed Summary

The central objective of this project is to obtain proof-of-concept data demonstrating the effects of propranolol (a beta-adrenergic antagonist) on neurobiological responses to personal smoking environments and behavioral responses in a laboratory smoking behavior task. Human cigarette smokers (N = 50) will take photographs of locations where they do and do not smoke cigarettes. They will then be randomly assigned to receive either propranolol (40 mg) or placebo prior to completing: A) An MRI session assessing neural responses to personal smoking/non-smoking environments, standard smoking/non-smoking environments and proximal smoking/non-smoking cues; and B) A laboratory session examining smoking behavior in response to environmental cues.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedOct 16, 2017
Enrollment StartJan 16, 2018
Primary CompletionJul 15, 2019
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 8.7 years ago

Interventions

Propranololdrug

Participants will take one dose of Propranolol (40mg IR) on two separate occasions.

Placebodrug

Participants will take one dose of Placebo on two separate occasions.